Where does CG Oncology's cash flow data come from?

Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

CG Oncology CGON Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$186.75M-16.0%	-$161M-6.3%	-$151.48M-18.3%	-$128.08M-21.3%	-$105.56M-19.9%
Depreciation and amortization	$2.26M+56.5%	$1.45M+142%	$596K+197%	$201K+287%	$52K+62.5%
Stock-based compensation	$28M+5.0%	$26.68M+9.0%	$24.48M+23.7%	$19.8M+31.7%	$15.04M+31.9%
Change in accounts receivable	——	——	——	——	——
Change in inventories	——	——	——	——	——
Change in accounts payable	$664K+140%	-$1.64M-138%	$4.28M—	——	——
Change in accrued liabilities	——	——	——	$15.84M+51.9%	$10.43M+90.8%
Change in other assets	$9.42M+396%	$1.9M+104%	$932K-28.5%	$1.3M—	——
Change in other liabilities	——	——	——	——	——
Other working capital changes	——	——	——	——	——
Net gains (losses) on investments	——	——	——	——	——
Net cash from operating activities	-$160.01M-20.9%	-$132.35M-13.3%	-$116.79M-24.5%	-$93.82M-14.4%	-$81.98M-4.1%
Capital expenditures	$422K+215%	$134K-60.1%	$336K+40.6%	$239K0.0%	$239K+1.7%
Purchases of investments	$1.29B+21.1%	$1.07B+8.2%	$987.19M+7.8%	$916.16M-4.0%	$954.54M-8.7%
Proceeds from maturities/sales of investments	$896.85M+6.2%	$844.14M-0.7%	$850.08M+6.3%	$799.94M0.0%	$799.69M+7.3%
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of common stock	$538.32M+265%	$147.45M-45.4%	$269.82M+20.6%	$223.68M—	——
Taxes paid for net share settlement	——	——	——	——	——
Net cash from financing activities	$546.43M+255%	$153.89M-44.7%	$278.23M+23.1%	$226.03M0.0%	$226.07M-64.0%
Net increase (decrease) in cash	——	——	——	-$10.53M—	——
Interest paid	$124.25K+20.6%	$103K—	——	——	——
Income taxes paid	——	——	——	——	——
Accrued expenses and other liabilities	——	——	——	$15.84M+51.9%	$10.43M+90.8%
Other long-term liabilities	——	——	——	——	——
Increase (Decrease) in Other Operating Assets	$2.57M+60.0%	$1.61M+1,835%	$83K+9.2%	$76K-1.3%	$77K+2.7%
Increase (Decrease) in Prepaid Expense and Other Assets	$9.42M+396%	$1.9M+104%	$932K-28.5%	$1.3M—	——
Non Cash Lease Expense	$61K+79.4%	$34K+113%	$16K+300%	$4K+112%	-$33K-50.0%
Other Noncash Income (Expense)	——	——	——	——	——
Payments to notes receivables	——	——	——	——	——
Proceeds from disposition of marketable securities and other investments	——	——	——	——	——
Payments Of Stock Issuance Costs	——	——	——	——	$2.8M-18.2%
Conversion Of Stock Issuance Costs	——	——	——	——	——
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	$859K—
Stock Issuance Costs Accrued But Not Yet Paid	——	——	——	——	——
Unrealized Gain (Loss) on Investments	——	——	——	——	——
Free cash flow	-$160.43M-21.1%	-$132.48M-13.1%	-$117.13M-24.5%	-$94.06M-14.4%	-$82.22M-4.1%
Free cash flow	-$160.43M-21.1%	-$132.48M-13.1%	-$117.13M-24.5%	-$94.06M-14.4%	-$82.22M-4.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does CG Oncology's cash flow data come from?: Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.